Figure 2. Overexpression of SSH1 is a biomarker of poor prognosis in patients with HCC. (A) Graphical representation (left) and statistical chart (right) showing the AUCs of TCGA-LIHC, TIGER-LC, GSE14520, GSE25097, GSE39791, GSE36376 of the non-tumor vs tumor samples. Kaplan-Meier plots of the (B) overall survival, and (C) progression-free survival in patients with high or low SSH1 expression from the TCGA-LIHC cohort. Forest plots of the (D) overall survival, and (E) progression-free survival based on SSH1 expression-based hazard ratios in patients with HCC from 23 different cancer types of the TCGA. All data are presented as means ± standard deviations of at least three independent experiments.